Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Código QR

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma

Kenji Inoue,1 Mayumi Iwasa,1 Masato Wakakura,1 Goji Tomita21Inouye Eye Hospital, 2Toho University Ohashi Medical Center, Tokyo, JapanBackground: The purpose of this study was to evaluate the effects of benzalkonium (BAK)-free travoprost monotherapy administered for 3 years on intraocular pressure an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Inoue K, Iwasa M, Wakakura M, Tomita G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/916ad6add731444f96ec4e62b072a7bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado AS, et al.
Publicado: (2011)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Gregory Katz, et al.
Publicado: (2010)

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2013)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Sophia K Mirza, et al.
Publicado: (2010)

The diurnal and nocturnal effects of travoprost in normal-tension glaucoma
por: Seibold LK, et al.
Publicado: (2014)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
por: Inoue K, et al.
Publicado: (2014)

Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma
por: Yuya Nomura, et al.
Publicado: (2010)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: David A Godfrey, et al.
Publicado: (2009)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: J Charles Henry, et al.
Publicado: (2008)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2012)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Michael J Miyashiro, et al.
Publicado: (2010)

Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects
por: Mizoue S, et al.
Publicado: (2014)

Serum free fatty acids levels not associated with normal tension glaucoma
por: Kenya Yuki, et al.
Publicado: (2010)

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from &szlig;-blockers and prostaglandin analogs
por: Inoue K, et al.
Publicado: (2012)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi M, et al.
Publicado: (2014)

Optic disc topography in Malay patients with normal-tension glaucoma and primary open-angle glaucoma
por: Adlina AR, et al.
Publicado: (2014)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
por: Inoue K, et al.
Publicado: (2012)

Superior segmental optic nerve hypoplasia accompanied by progressive normal-tension glaucoma
por: Yamazaki Y, et al.
Publicado: (2012)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients
por: Tsumura T, et al.
Publicado: (2014)

Investigation of the association between the GLC3A locus and normal tension glaucoma in Japanese patients by microsatellite analysis
por: M Kamio, et al.
Publicado: (2009)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
por: Emilio Rintaro Suzuki Jr, et al.
Publicado: (2010)

Selective laser trabeculoplasty reduces mean IOP and IOP variation in normal tension glaucoma patients
por: Mohammed K El Mallah, et al.
Publicado: (2010)

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
por: Quaranta L, et al.
Publicado: (2015)

Association of microsatellite polymorphisms of the GPDS1 locus with normal tension glaucoma in the Japanese population
por: Kayo Nakamura, et al.
Publicado: (2009)

Optic disc size and progression of visual field damage in patients with normal-tension glaucoma
por: Hayamizu F, et al.
Publicado: (2013)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
por: Tsumura T, et al.
Publicado: (2015)

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
por: Inoue K, et al.
Publicado: (2020)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Corrigendum: Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
por: Suzuki CLB, et al.
Publicado: (2010)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
por: Tsumura T, et al.
Publicado: (2015)

Continuous 24-hour ocular dimensional profile recording in medically treated normal-tension glaucoma
por: Lee JWY, et al.
Publicado: (2015)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão MLS, et al.
Publicado: (2014)

BAK additive influence on results
por: Shah RD, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura T, et al.
Publicado: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Efficacy and tolerability of a large scale change in regimen from latanoprost to travoprost in glaucoma patients at the Manhattan Veterans Administration Hospital
por: Edmund P Farris
Publicado: (2008)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
por: Tsumura T, et al.
Publicado: (2013)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
por: Lanzl I, et al.
Publicado: (2013)